Astrazeneca Ab

Marc Chapdelaine

John McCauley

Daniel Sohn

Carey Horchler

Timothy Davenport

Edward Pierson

Markus Haeberlein

Lucius Kemp

Greg A Hostetler

Cyrus Ohnmacht

Hui-Fang Chang

Bruce Thomas Dembofsky

Christopher Becker

Suzanne J Suchard

Glen E Ernst

Rebecca Urbanek

Gary Steelman

Keith John Herzog

Bipinchandra Chaudhari

Katherine Knappenberger

Linda Sygowski

Chris Allan Veale

Dannielle Kissel

This invention encompasses nicotinic acetylcholine receptor reactive compounds in accord with formula (I) Wherein: D represents O; E represents CH2, NH, O or S; n is 1 or 2 and stereoisomers, enantiomers, in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of such compounds, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.

Compounds and uses thereof

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R, Rand Rare any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.

N-type calcium channel antagonists for the treatment of pain

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Therapeutic heterocyclic compounds

Provided herein is a compound having the formula (I):Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTantagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Therapeutic chromone compounds

Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Qat each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C-C) alkyl and C(O)phenyl, and Qis selected from hydrogen, halogen, O&#x2014;(C-C)alkyl, O&#x2014;(C-C)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NOor halogen, and indolyl may be substituted with (C-C)alkyl or phenyl

Cd45 inhibitors

Compounds useful for the treatment of pain in accord with the following structural diagram,wherein R, R, R, Rand Rare any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

Compounds having selective action at neuronal N-type calcium channels useful for the treatment of pain in accord with the following structural diagram,wherein R, Rand Rare a variety of groups as defined in the specification.

Growing community of inventors

Wilmington, DE, United States of America

Marc Chapdelaine